Geoffrey M Lowman (Geoffrey Lowman)

Years Active: 2021-2023
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Bettzy Stephen, Joud Hajjar, Shrutii Sarda, Dzifa Yawa Duose, Jeffrey M Conroy, Carl Morrison, Anas Alshawa, Mingxuan Xu, Abdulrazzak Zarifa, Sapna Pradyuman Patel, Ying Yuan, Evan Kwiatkowski, Linghua Wang, Jordi Rodon Ahnert, Siqing Fu, Funda Meric-Bernstam, Geoffrey M Lowman, Timothy Looney, Aung Naing
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy. Journal for immunotherapy of cancer 11 (8) (2023)
Walter J Storkus, Deena Maurer, Yan Lin, Fei Ding, Anamika Bose, Devin Lowe, Amy Rose, Melissa DeMark, Lilit Karapetyan, Jennifer L Taylor, Manoj Chelvanambi, Ronald J Fecek, Jessica N Filderman, Timothy J Looney, Lauren Miller, Elizabeth Linch, Geoffrey M Lowman, Pawel Kalinski, Lisa H Butterfield, Ahmad A Tarhini, Hussein A Tawbi, John M Kirkwood
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. Journal for immunotherapy of cancer 9 (11) (2022)
Takayasu Ideta, Boyang Li, Christopher Flynn, Yuichi Igarashi, Geoffrey M Lowman, Tim Looney, Thomas J Devers, John Birk, Faripour Forouhar, Charles Giardina, Daniel W Rosenberg
The Epithelial-Stromal Microenvironment in Early Colonic Neoplasia. Molecular cancer research : MCR (2021)

Geoffrey M Lowman.css-eqlu8i{font-size:small;padding-left:4px;} (Geoffrey Lowman)